Exact Mass: 433.1572378
Exact Mass Matches: 433.1572378
Found 166 metabolites which its exact mass value is equals to given mass value 433.1572378,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
(2R)-1-[4-[1,3-Benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
C21H27N3O3S2 (433.14937520000007)
2-Methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents
4-Nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
C24H23N3O5 (433.16376280000003)
1-(2-Methyl-4-methoxyphenyl)-4-((2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline
D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors
Sarpicillin
C21H27N3O5S (433.1671332000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide
C21H27N3O3S2 (433.14937520000007)
Nitrile,1-O-beta-rutinoside-glucopyranoside,penta-Ac-1,4-Dihydroxy-2-cyclopentene-1-carboxylic acid
C18H27NO11 (433.15840319999995)
12-[(2,4-dimethoxyphenyl)carbonyl]-6a,6b,10,11,11a,12-hexahydro-8,11-epoxyoxepino[4,5:3,4]pyrrolo[1,2-a]quinolin-7(8H)-one
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.276 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.275 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.279
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate
C23H28ClNO5 (433.1655908000001)
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based on: CCMSLIB00000846974]
C23H28ClNO5 (433.1655908000001)
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based: Match]
C23H28ClNO5 (433.1655908000001)
Cys Asn Pro Thr
Cys Asn Thr Pro
Cys Pro Asn Thr
Cys Pro Gln Ser
Cys Pro Ser Gln
Cys Pro Thr Asn
Cys Gln Pro Ser
Cys Gln Ser Pro
Cys Ser Pro Gln
Cys Ser Gln Pro
Cys Thr Asn Pro
Cys Thr Pro Asn
Asp Gly Gly Trp
Asp Gly Trp Gly
Asp Trp Gly Gly
Gly Asp Gly Trp
Gly Asp Trp Gly
Gly Gly Asp Trp
Gly Gly Trp Asp
Gly Trp Asp Gly
Gly Trp Gly Asp
Asn Cys Pro Thr
Asn Cys Thr Pro
Asn Pro Cys Thr
Asn Pro Thr Cys
Asn Thr Cys Pro
Asn Thr Pro Cys
Pro Cys Asn Thr
Pro Cys Gln Ser
Pro Cys Ser Gln
Pro Cys Thr Asn
Pro Asn Cys Thr
Pro Asn Thr Cys
Pro Gln Cys Ser
Pro Gln Ser Cys
Pro Ser Cys Gln
Pro Ser Gln Cys
Pro Thr Cys Asn
Pro Thr Asn Cys
Gln Cys Pro Ser
Gln Cys Ser Pro
Gln Pro Cys Ser
Gln Pro Ser Cys
Gln Ser Cys Pro
Gln Ser Pro Cys
Ser Cys Pro Gln
Ser Cys Gln Pro
Ser Pro Cys Gln
Ser Pro Gln Cys
Ser Gln Cys Pro
Ser Gln Pro Cys
Thr Cys Asn Pro
Thr Cys Pro Asn
Thr Asn Cys Pro
Thr Asn Pro Cys
Thr Pro Cys Asn
Thr Pro Asn Cys
Trp Asp Gly Gly
Trp Gly Asp Gly
Trp Gly Gly Asp
1H-Pyrazole-4-carboxamide,5-chloro-N-[2-[(3,7-dimethyl-2-quinolinyl)amino]ethyl]-3-methyl-1-phenyl-(9CI)
4-BROMO-N-DODECYL-1-HYDROXY-2-NAPHTHALENECARBOXAMIDE
Sarpicillin
C21H27N3O5S (433.1671332000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
4-Aminophenyl-beta-D-lactopyranoside
C18H27NO11 (433.15840319999995)
Fluvastatin sodium
C24H25FNNaO4 (433.16652220000003)
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer?of Fluvastatin. Fluvastatin is a first fully synthetic, competitive?HMG-CoA reductase?inhibitor with an IC50?of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].
Lubeluzole
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D002317 - Cardiovascular Agents D020011 - Protective Agents
(4-Nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate
C24H23N3O5 (433.16376280000003)
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively[1].
N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide
C21H27N3O3S2 (433.14937520000007)
1-(4-(Benzo[d]thiazol-2-yl(methyl)amino)piperidin-1-yl)-3-(3,4-difluorophenoxy)propan-2-ol
(3r,5s)-Fluvastatin sodium
C24H25FNNaO4 (433.16652220000003)
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors (3R,5S)-Fluvastatin ((3R,5S)-XU 62-320) sodium is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
C21H27N3O3S2 (433.14937520000007)
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
C21H27N3O3S2 (433.14937520000007)
N-{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl}-2-methylpropanamide
4-chloro-N-[2-(1H-indol-3-yl)-1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)ethyl]benzamide
N-(2,5-dimethoxyphenyl)sulfonyl-N-(4-methoxyphenyl)cyclohexanecarboxamide
C22H27NO6S (433.1559002000001)
4-[2-Benzofuranyl(oxo)methyl]-1-[2-(4-morpholinyl)ethyl]-5-(3-pyridinyl)pyrrolidine-2,3-dione
C24H23N3O5 (433.16376280000003)
N-[(2R,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
C20H24ClN5O4 (433.15167340000005)
N-[(2R,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
C20H24ClN5O4 (433.15167340000005)
2-[(2R,3S,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,3S,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3R,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
N-[(2R,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
C20H24ClN5O4 (433.15167340000005)
(1R,2aS,8bS)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,2aR,8bR)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
[(2S,3R)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
[(2S,3S)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
N-[(2R,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
C20H24ClN5O4 (433.15167340000005)
N-[(2S,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
C20H24ClN5O4 (433.15167340000005)
N-[(2S,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
C20H24ClN5O4 (433.15167340000005)
2-[(2S,3R,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3S,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
N-[(2S,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
C20H24ClN5O4 (433.15167340000005)
N-[(2S,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
C20H24ClN5O4 (433.15167340000005)
(1S,2aR,8bR)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1S,2aS,8bS)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
cyclobutyl-[(1S)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
C21H27N3O5S (433.1671332000001)
[(2R,3R)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
cyclobutyl-[(1R)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
C21H27N3O5S (433.1671332000001)
5-(3,4-Dimethoxyphenyl)-4-(furan-2-carbonyl)-1-(2-phenylethyl)pyrrolidine-2,3-dione
Fluvastatin (sodium)
C24H25FNNaO4 (433.16652220000003)
Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].
(7s)-5-chloro-3-[(1e,3e,5r)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
(1r,4s)-4-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}cyclopent-2-ene-1-carbonitrile
C18H27NO11 (433.15840319999995)
(2e)-n-[2-(4-{[(2e)-3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methanesulfonylprop-2-enimidic acid
C22H27NO6S (433.1559002000001)
(7r)-5-chloro-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
(7r)-5-chloro-3-[(1e,3z,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
1-{[3,4-dihydroxy-6-(hydroxymethyl)-5-[(4,5,6-trihydroxy-3-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-4-hydroxycyclopent-2-ene-1-carbonitrile
C18H27NO11 (433.15840319999995)
n-[2-(4-{[3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methanesulfonylprop-2-enimidic acid
C22H27NO6S (433.1559002000001)
4-hydroxy-1-[(3,4,5-trihydroxy-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-2-yl)oxy]cyclopent-2-ene-1-carbonitrile
C18H27NO11 (433.15840319999995)
4-[(4,5,6-trihydroxy-3-methyloxan-2-yl)oxy]-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclopent-2-ene-1-carbonitrile
C18H27NO11 (433.15840319999995)
(1s,4s)-4-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}cyclopent-2-ene-1-carbonitrile
C18H27NO11 (433.15840319999995)
(1s,4r)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}cyclopent-2-ene-1-carbonitrile
C18H27NO11 (433.15840319999995)
4-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}cyclopent-2-ene-1-carbonitrile
C18H27NO11 (433.15840319999995)
(7s)-5-chloro-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
5-chloro-3-(3,5-dimethylhepta-1,3-dien-1-yl)-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)